Clinical Trial

Maternal Serum Adropin in Placenta Accreta Spectrum

Study acronym: Adropin
Completed
View on ClinicalTrials.gov →
Summary
Aim: To compare maternal serum adropin levels in pregnancies complicated by placenta previa and/or placenta accreta spectrum (PAS) with those of healthy pregnant women and to evaluate the diagnostic value of adropin for predicting placental invasion. Methods: This cross-sectional study included 84 singleton pregnancies at ≥34 weeks of gestation: 42 women diagnosed with placenta previa and/or PAS and 42 healthy pregnant women who underwent cesarean delivery. Maternal serum adropin levels are measured preoperatively using enzyme-linked immunosorbent assay. Demographic, obstetric, ultrasonographic, and intraoperative findings were recorded. Receiver operating characteristic (ROC) curve analysis is performed to assess the predictive performance of adropin for PAS.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-12.
Trial Details
NCT Number NCT07421180
Lead Sponsor Adana City Training and Research Hospital
Conditions Placenta Accreta Spectrum, Placenta Previa
Enrollment 84 participants
Start Date 2024-05-15
Primary Completion 2025-04-01 (estimated)
Study Completion 2025-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-20